Month: May 2014

Topically administered lyophilized amnion fragments a possible alternative to graft surgery

MILAN — Freeze-dried amniotic membrane elements administered to the eye topically represent a revolutionary transplantation technique without the use of surgery, according to a presenter here.The technique, called elemental unit transplantation, is the result of 12 years of research by Kenneth R. Kenyon, MD, and Emiliano Ghinelli, MD. Ghinelli presented the technique, which was recently approved by the Institute of Health in Italy, at the annual joint meeting of Ocular Surgery News and the Italian Society of Ophthalmology.

Air bubble stops bleeding, avoids pressure spikes during phaco in glaucoma patients

MILAN — Injecting an air bubble into the anterior chamber may help stop hyphema while also avoiding pressure spikes during cataract surgery in patients with glaucoma, according to a surgeon here.“Studies have shown that intraoperative IOP rises above 30 mm Hg in 10% of uncomplicated phaco cases. In glaucoma patients, the high pressure tends to persist into the following week,” Steven Dewey, MD, said at the annual joint meeting of Ocular Surgery News and the Italian Society of Ophthalmology.

BLOG: Ethical dilemmas; insurers offer doctors bonuses for using cheaper medications

An article in Tuesday’s Wall Street Journal describes a new payment incentive from WellPoint Health Insurance for oncologists treating breast cancer, in which doctors receive a $350 per month bonus payment for using an insurance-approved chemotherapy regimen. The approved regimen has been described by leading specialists in the field as reasonable for the majority of patients but is certainly not an ideal fit for everyone.

New-generation, pre-loaded MICS lens produces good FDA trial results

MILAN — The new-generation Hoya 251 IOL for microincision, already available in Europe and Asia, has emerged from its U.S. Food and Drug Administration trial with good outcomes, according to a surgeon here. “The previous three-piece model available for a decade has transitioned to a one-piece. The lens is preloaded into a dedicated inserter, which can be used to gently guide the lens to [unfold]. The PMMA non-stick haptic tips help the lens to easily self-position in the bag. The aspheric balanced curve optic design provides excellent visual quality and (Read more...)

Allergan issues concerns about viability of Valeant’s business model

Allergan filed an investor presentation with the Securities and Exchange Commission outlining its concerns about the fiscal and operational stability of Valeant Pharmaceuticals, the company announced in a press release.According to the release, Allergan retained the financial consultant Alvarez & Marsal and the forensic accounting firm FTI Consulting to analyze issues surrounding the intrinsic value of Valeant’s business model and stock.

Strampelli Medal Lecture highlights continuous evolution of OVDs

MILAN, Italy – The continuous evolution of ophthalmic viscosurgical devices has gone hand in hand with major advances in ocular surgery, making the devices an indispensable tool for addressing new types of surgery, according to Steve Arshinoff, MD.  Arshinoff, the Benedetto Strampelli Medal Lecturer at the joint meeting of Ocular Surgery News and the Italian Society of Ophthalmology, discussed the history of ophthalmic viscosurgical devices (OVDs), from the first high-viscosity, cohesive Healon (sodium hyaluronate)— patented by Endre Balazs, MD, and sold globally  in 1980 — to the contest between Healon (Read more...)

STAAR announces 12% revenue increase in Q1 2014

STAAR Surgical reported 2014 first quarter revenue of $20.2 million, demonstrating a 12% increase from the first quarter of 2013, according to a company press release.“We are off to a very good start in 2014 with revenue growth of 12% and 15% growth in constant currency, which was driven by [Visian implantable collamer lens] and IOL new product sales,” Barry Caldwell, STAAR Surgical president and CEO, said in the release.

Valeant reports 77% first-quarter revenue increase

Valeant Pharmaceuticals reported revenue of $1.9 billion in the first quarter of 2014, an increase of 77% compared with last year’s earnings, according to a press release.The company also reported an increase in its developed market revenue of $1.4 billion, up 82% from the first quarter of 2013 as a result of promoted dermatology brands, consumer, neurology and other, and oral health businesses, as well as a 9% organic growth in Bausch + Lomb businesses, the release said.

Physician customers offer support for Allergan’s rejection of Valeant’s unsolicited acquisition proposal

Allergan received more than 500 letters from its physician customers, as well as from various patient advocacy groups and medical associations, in support of its decision to reject Valeant Pharmaceutical’s unsolicited proposal to acquire the company, according to a press release.“All of us at Allergan are deeply touched that our customers have taken the time to write to tell us that our work has mattered to them and their patients, and to publicly share their support and encouragement for our company’s business model and our promising future,” David E.I. Pyott, (Read more...)